TT30 is an FH and CR2 fusion protein that has been designed to selectively inhibit the AP locally at activation sites in order to minimize the risk of infection or autoimmune disease which could increase upon systemic complement inhibition (Figure 3B) (203). The gene discussed is CR2; the disease is infection.